Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
121152	15/WM/0268	180158	Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma	No		15			17/03/2017	14/08/2017		24/08/2017	29/08/2017	Please Select...	31/08/2017	I - Rare diseases	There were pharmacy issues regarding excess treatment costs. This was relevant to the normal care pathway of the patients	NHS Provider
121153	16/NW/0496	169304	RESILIENT: RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide LAR versus dapagliflozin alone in obese (BMI>30 kg/m2) patients with Type 2 diabetes mellitus.	No		29			27/10/2015	30/08/2017	12/06/2017	26/09/2017	28/09/2017	Please Select...		D - Sponsor Delays	Confirm CC from the Trust but green light still awaited from Sponsor	Sponsor
121154	17/EM/0183	220783	A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal polyps Protocol Number: 205687	Yes	01/12/2017	7	45	52	26/07/2016	10/10/2017	28/06/2017	11/10/2017	17/10/2017	Please Select...	17/10/2017			Please Select...
121155	15/YH/0478	186697	A Phase 3, DoubleBlind, Randomized, LongTerm, PlaceboControlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Yes	01/12/2017	84	24	108	20/04/2017	15/08/2017	26/04/2016	24/10/2017	07/11/2017	Please Select...	07/11/2017	J - Other	Pathology Service department external to the Trust	Neither
121156	17/EM/0192	223856	A Phase 2, 24-week, Randomized, Double - Blind. Placebo - Controlled, Multicenter Study, Followed by a 24	No		0			25/05/2017	07/11/2017	14/09/2017	25/10/2017	07/11/2017	Please Select...	07/11/2017	I - Rare diseases	Very rare condition	Neither

			- Week Extension, to Evaluate the Efficacy and Safety of CC - 90001 in Subjects with Idiopathic Pulmonary Fibrosis															
121157	10/H0604/51	43801	Natural history and pathogenesis of systemic IgG4 disease	No		100			04/05/2017	01/08/2017	30/08/2016	01/09/2017	09/11/2017	Please Select...	09/11/2017	E - Staff availability issues	Staff workload issues	NHS Provider
121158	17/LO/1116	225233	SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of secukinumab in controlling spinal pain in patients with axial spondyloarthritis	No		3			16/08/2017	15/12/2017	09/10/2017	08/12/2017	18/12/2017	Please Select...	18/12/2017	D - Sponsor Delays	Green light not issued until 4 weeks after CC confirmed	Sponsor
121159	17/SC/0237	220963	A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase 2a study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a 12 week treatment period compared to placebo in patients with clinical evidence of NASH	Yes	16/01/2018	1	41	42	04/10/2017	05/12/2017	17/10/2017	24/11/2017	06/12/2017	Please Select...	13/12/2017			Please Select...
121160	17/SW/0127	225959	A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.	No		9			27/10/2017	27/11/2017	03/07/2017	27/11/2017	06/12/2017	Please Select...	09/01/2018	I - Rare diseases	Very rare condition	Neither
121161	16/NW/0575	210424	A multicentre, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan, on cognitive function as assessed by neurocognitive battery in patients with chronic heart failure with preserved ejection fraction	No		20			25/08/2016	13/02/2018	05/12/2016	07/02/2018	05/03/2018	Please Select...	05/03/2018			Please Select...

121162	11/WM/0367	60187	immunotace: A Randomised phase II Clinical Trial of conditioning cyclophosphamide and Chemoembolisation with or without Vaccination with Dendritic Cells pulsed with HepG2 lysate ex vivo in Patients with Hepatocellular Carcinoma	Yes	22/03/2018	25	24	49	25/01/2017	01/02/2018	30/12/2016	14/02/2018	26/02/2018	Please Select...	27/02/2017			Please Select...
121163	17/EM/0315	220334	Trial 1: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease	No		20			31/05/2017	14/02/2018	03/11/2017	14/02/2018	06/03/2018	Please Select...		J - Other	Following CC. Capacity issues arose within the Service departments due to radiology staffing levels	NHS Provider
121164	17/LO/0334	214459	Floella: Open, multicentre, randomised controlled trial of cardiac output-guided haemodynamic therapy compared to usual care in patients undergoing emergency bowel surgery	Yes	19/03/2018	7	28	35	17/08/2017	12/02/2018	29/03/2017	13/02/2018	19/02/2018	Please Select...	13/03/2018			Please Select...
121165	17/NW/0517	232120	Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study)	Yes	02/03/2018	58	30	88	17/10/2017	04/12/2017	16/10/2017	18/01/2018	31/01/2018	Please Select...	27/02/2018	D - Sponsor Delays	Sponsor delay issuing Green Light to Trust	Sponsor
121166	16/YH/0459	213518	A multicentre, double-blind, centre-stratified multi-period crossover trial to evaluate the efficacy of the Optimal Pathwat for TreatOng neurOpathic paiN in Diabetes Mellitus (OPTION-DM)	Yes	27/02/2018	13	28	41	27/11/2017	17/01/2018	24/07/2017	22/01/2018	30/01/2018	Please Select...	08/02/2018			Please Select...
121167	18/SW/0025	240991	Reducing 30-day Emergency Readmission in Dialysis Patients using Discharge Care Pathway	Yes	01/02/2018	0	1	1	27/12/2017	31/01/2018	29/01/2018	31/01/2018	31/01/2018	Please Select...	31/01/2018			Please Select...
121305	18/WA/0001	238609	A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Treating Pain	No		12			05/09/2017	06/06/2018	23/03/2018	13/06/2018	18/06/2018	Please Select...	18/06/2018			Please Select...

			Experienced by Subjects With Confirmed Small Fibre Neuropathy That is Idiopathic or Associated With Diabetes Mellitus														
121306	18/NW/0241	236137	A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Obese Subjects	Yes	28/06/2018	4	38	42	19/09/2017	17/05/2018	16/05/2018	14/05/2018	21/05/2018	Please Select...	31/05/2018			Please Select...
121307	17/NE/0239	222301	Nasal AIRway Obstruction Study	No		0			03/10/2017	06/06/2018	31/08/2017	06/06/2018	06/06/2018	Please Select...	12/06/2018			Please Select...
121308	17/SC/0616	232772	A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)	Yes	25/04/2018	0	19	19	06/09/2017	06/04/2018	11/12/2017	12/03/2018	06/04/2018	Please Select...	09/04/2018			Please Select...
121326	18/NW/0172	242180	Effects and safety of semaglutide 2.4mg once-weekly in subjects with overweight or obesity	Yes	06/07/2018	11	35	46	19/03/2018	21/05/2018	17/05/2018	23/05/2018	01/06/2018	Please Select...	01/06/2018			Please Select...
121327	17/SW/0221	232448	A randomized, partially-blinded, active-controlled,multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis	No		0			27/02/2018	10/05/2018	28/11/2017	23/04/2018	10/05/2018	Please Select...	07/06/2018			Please Select...